Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
AbstractPsoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.
Authors: Yadav SR, Kumar R, Gupta N, Ish P, Chakrabarti S, Kumar A Abstract To the Editor Novel Coronavirus disease (COVID-19) was first notified in December 2019 from Wuhan, China. Now, it has spread rapidly and has been declared a pandemic affecting over 200 countries with widespread morbidity and mortality. It has been postulated that the most vulnerable population are the elderly, people living in crowded areas, children and immune-compromised individuals, such as people living with human immunodeficiency virus (HIV). The correlation of tuberculosis (TB), HIV and malnutrition are well documented and hence, peop...
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including in the CNS and the immune system. Whether bile acid metabolism is abnormal in MS is unknown. Using global and targeted metabolomic profiling, we identified lower levels of circulating bile acid metabolites in multiple cohorts of adult and pediatric patients with MS compared with controls. In white matter lesions from MS brain tissue, we noted the presence of bile acid receptors on immune and glial cells. To mechanistically examine the ...
What do we currently know about the costs associated with hepatitis A-related hospitalizations?Emerging Infectious Diseases
Publication date: September 2020Source: International Journal of Paleopathology, Volume 30Author(s): Ellie Gooderham, Luísa Marinho, Laure Spake, Shera Fisk, Carlos Prates, Sandra Sousa, Carlos Oliveira, Ana Luisa Santos, Hugo F.V. Cardoso
Authors: Piraccini E, Calli M, Taddei S, Byrne H, Rocchi M, Maitan S PMID: 32449341 [PubMed - as supplied by publisher]
Authors: Abdelhamid BM, Khaled D, Mansour M, Hassan MM Abstract BACKGROUND: Pain control in the morbidly obese has presented as an anesthetic challenge. The aim of this study is to assess the analgesic efficacy of ultrasound guided bilateral erector spinae block compared to bilateral subcostal transversus abdominis plane block. METHODS: Prospective randomized, double-blinded controlled study was conducted at Kasr Alainy Hospital on 66 patients scheduled for laparoscopic sleeve gastrectomy. Patients were randomly allocated into three groups and received general anesthesia: bilateral erector spinae block at the l...
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): S. El-Wahsh, H. Bogaardt, F. Kumfor, K. Ballard
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Juan Zhang, Yong-Feng Xu, Lei Wu, Hong-Fu Li, Zhi-Ying Wu
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): A Droby, L Fleysher, M Petracca, K Podranski, J Xu, M Fabian, M Marjańska, M Inglese
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Kejia Zhang, Yinlong Zhao, Zhenzhen Liang, Chunpeng Wang, Xin Liu